Re-Engineering the Therapeutic Window: Can Pre-Targeting Overcome the Fundamental Limitations of Conventional Radiopharmaceuticals?
1:30 pm - Wednesday 2nd December 2026
- Examining how the pharmacokinetic coupling of tumor targeting and radionuclide delivery constrains the therapeutic window of conventional radiopharmaceuticals
- Exploring how pre-targeting separates tumor localization from radionuclide administration to improve tumor-to-non-tumor tissue exposure and enable more flexible radionuclide delivery
- Sharing lessons learned from candidate selection, platform optimization, and preclinical development in advancing next-generation pre-targeting technologies
- Identifying the target characteristics and disease settings most likely to benefit from pre-targeting and unlock previously inaccessible therapeutic opportunities
